Participating men randomized to the intervention underwent PSA testing. Those with a PSA level of 3.0 ng/mL or higher underwent additional testing for high-grade prostate cancer with a 4-kallikrein panel risk score. Those wi...
1.1纳入标准本研究设定的纳入标准为:1.经过病理检查明确诊断原发肿瘤为的前列腺癌;2确诊时间在2004年至2014年之间;3.病理类型符合前列肿瘤(国际肿瘤疾病分类ICDO-3编码为C61.9)和腺癌(编码8140/3);4.具有完整生存时间;5.PSA水平小于等于10ng/ml、Gleason评分8-10。1.2排除标准1.无有效随访时间或生存时间不完整;...
(2014) 110, 2829–2836 | doi: 10.1038/bjc.2014.242 Keywords: cluster randomised controlled trial; screening; prostate cancer; prostate-specific antigen; prostate cancer mortality; cost-effectiveness Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate ...
The EMR was queried using ICD-9 and CPT codes for diagnoses and procedures. We identified patients older than 35 years who underwent an initial PSA test from 1999 to 2012. Patients with a diagnosis of prostate cancer prior to PSA testing were excluded from the study. The Deyo classification ...
(accessed under Application Number: 24711) consists of 11,178 men with symptomatic BPH/LUTS, according to hospital-based diagnosis (ICD10 code = N40), as well as 176,541 male controls, not known to have been diagnosed with BPH/LUTS. For the UK GWAS of prostate cancer (ICD10 code...